News | March 24, 2025
AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Prior to joining Neuland, Deshmukh held several key positions at Cipla
The company has also launched its first three 24*7 pharmacy stores via COCO model in Bengaluru
Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
This addition strengthens Dr. Agarwals Eye Hospital's vast network of 28 hospitals across Karnataka and 220+ facilities worldwide
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
This achievement underscores the company’s steadfast commitment to sustainability, corporate responsibility, and ESG excellence
Nadda also commended the role of ASHA workers, “grassroot foot soldiers”, in the healthcare system
Subscribe To Our Newsletter & Stay Updated
